Bharat Biotech said reasons such as low procurement volumes, high distribution costs and retail margins among others contribute to the higher pricing of Covaxin.
The Drugs Controller General of India had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on 12 May.
The company asserted that it has published as many as 9 research studies on the safety and efficacy of Covaxin in five reputed peer-reviewed journals in a span of 12 months.
NITI Aayog member V K Paul said that he respected US' decision and hoped that the vaccine manufacturer will comply with the parameters of their regulatory system.
Bharat Biotech's US partner for Covaxin Ocugen Thursday said it will pursue full approval through a Biologics License Application, which may delay the vaccine launch in the country.
According to SOPs issued by the Union health ministry Monday, even in these cases, the second dose will only be administered after 28 days from the date of the first dose.
RSS chief Mohan Bhagwat has backtracked on his retirement rules. The ‘75-year rule’ was applied selectively to sideline some leaders, but it doesn’t apply to the top brass.
A public meeting, where the women voiced their protest, took place this month in Delhi, grounded on the findings of an AIDWA survey, covering 9,000 women borrowers.
Joint Doctrine for Special Forces Operations, released Wednesday, also outlines plans for the future expansion of AFSOD and the creation of Joint Service Training Institutes.
Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.
COMMENTS